Benzinga | Apr 6, 2021 06:38AM EDT

Aptinyx Recommences Phase 2 Study Of NYX-458 In Patients With Cognitive Impairment Associated With Parkinson's Disease Dementia And Dementia With Lewy Bodies; Note: Screening Was Previously Temporarily Suspended Due To COVID-19

Patient screening has resumed following temporary suspension due to escalation of the COVID-19 pandemic

Data readout from the Phase 2 cognitive impairment study expected in 2H 2022

Three Phase 2 data readouts expected over the next 12 to 18 months across the company's clinical development pipeline

Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has recommenced patient screening in a Phase 2 study of NYX-458 in patients with mild cognitive impairment and mild dementia associated with Parkinson's disease and dementia with Lewy bodies. The company anticipates reporting data from this study in the second half of 2022.

"We are pleased to be moving forward in evaluating NYX-458 in patients suffering from cognitive impairment," said Norbert Riedel, Ph.D., chief executive officer of Aptinyx. "Current therapies for these patients often do not deliver meaningful benefits and there is a great need for new therapeutic options. We believe the mechanism of NYX-458 is uniquely suited to address the cognitive deficits experienced by these patients and we look forward to building on the compelling preclinical data we have garnered with NYX-458 to date."

"Misfolded alpha-synuclein deposition can lead to NMDA glutamate receptor dysfunction and contribute to cognitive deficits that characterize patients with Parkinson's disease dementia and dementia with Lewy bodies," said Peter LeWitt M.D., Professor of Neurology at Wayne State University School of Medicine. "Modulation of NMDA glutamate receptors to address this underlying disease pathology is a compelling approach to treating the broad spectrum of symptoms associated with cognitive impairment. I look forward to seeing the data from this study, which offers a first step in understanding the potential for NYX-458 as a novel therapeutic option."